Related Experiment Video
Updated: Jan 20, 2026
09:56
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Published on: August 2, 2016
15.5K
[Cutaneous angiosarcoma : Radiochemotherapy with liposomal pegylated doxorubicin]
N Bönisch1, E A Langan1,2, P Terheyden3
1Klinik für Dermatologie, Universität zu Lübeck, Lübeck, Deutschland.
Summary
Combined radio- and chemotherapy using liposomal, pegylated doxorubicin offers a therapeutic option for cutaneous angiosarcoma. However, the short response duration highlights the urgent need for novel treatment strategies for this rare cancer.
Area of Science:
- Oncology
- Dermatology
- Medical Oncology
Background:
- Cutaneous angiosarcoma is a rare tumor primarily affecting elderly patients.
- Management is challenging due to the tumor's location and diffuse nature, often precluding complete surgical excision.
- Current treatments include chemotherapy and/or radiotherapy.
Purpose of the Study:
- To evaluate the efficacy of combined radio- and chemotherapy with liposomal, pegylated doxorubicin in cutaneous angiosarcoma patients.
- To assess treatment outcomes, including progression-free survival and overall survival.
Main Methods:
- Retrospective analysis of 6 cutaneous angiosarcoma patients treated between 2007 and 2018.
- All patients received radiotherapy combined with liposomal, pegylated doxorubicin (25 mg/m² every 2 weeks).
- Tumors were non-resectable in all cases.
Main Results:
- Mean progression-free survival was 8 months (range 5-14 months); mean overall survival was 13 months (range 13-34 months).
- Partial response observed in 4 patients; 1 patient had progressive disease.
- Two patients experienced severe adverse events, leading to therapy termination.
Conclusions:
- Combined radio- and chemotherapy with liposomal, pegylated doxorubicin is a viable option for cutaneous angiosarcoma.
- The short response rate necessitates the development of new therapeutic approaches for this condition.
